Who are Autologous UCB Reinfusion's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, MC, 3ml-Rejuvinex, (H) T-L14, ASC, Stempeucel®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/autologous-ucb-reinfusion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Autologous UCB Reinfusion — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Autologous UCB Reinfusion (Autologous UCB Reinfusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy. Area: Immunology, Regenerative Medicine.

phase 2 Cell therapy Immunology, Regenerative Medicine Biologic Live · refreshed every 30 min

Target snapshot

Autologous UCB Reinfusion (Autologous UCB Reinfusion) — Joanne Kurtzberg, MD. Autologous umbilical cord blood (UCB) cells are reinfused into patients to promote immune reconstitution and tissue repair.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Autologous UCB Reinfusion TARGET	Autologous UCB Reinfusion	Joanne Kurtzberg, MD	phase 2	Cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
MC	MC	Aivita Biomedical, Inc.	marketed	Mesenchymal stem cell therapy
3ml-Rejuvinex	3ml-Rejuvinex	Seoul National University Bundang Hospital	marketed	Autologous cell therapy
(H) T-L14	(H) T-L14	National Taiwan University Hospital	marketed	T-cell therapy	T-cells
ASC	ASC	Anterogen Co., Ltd.	marketed	Autologous stem cell therapy
Stempeucel®	Stempeucel®	Cell Biopeutics Resources Sdn Bhd	marketed	Allogeneic mesenchymal stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy class)

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · 2 drugs in this class
Bone Therapeutics S.A · 1 drug in this class
DiscGenics, Inc. · 1 drug in this class
Celavie Bioscences, LLC · 1 drug in this class
China Spinal Cord Injury Network · 1 drug in this class
City of Hope Medical Center · 1 drug in this class
Brainstorm-Cell Therapeutics · 1 drug in this class
Dr. Grant M. Pagdin · 1 drug in this class
FDA Office of Orphan Products Development · 1 drug in this class
Biosolution Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Autologous UCB Reinfusion — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-ucb-reinfusion. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab